Low-dose aspirin is not effective as an adjunct treatment for HIV infection among people living with HIV on dolutegravir-based antiretroviral therapy: A randomised double-blind, parallel-group placebo-controlled trial

Tosi M Mwakyandile, Grace A Shayo, Philip G Sasi, Peter P Kunambi, Ferdinand M Mugusi, Godfrey Barabona, Takamasa Ueno and Eligius F Lyamuya

PLOS ONE, 2025, vol. 20, issue 8, 1-17

Abstract: Background: Despite virologic suppression with antiretroviral therapy (ART), immune activation (IA) in people living with HIV (PLHIV) remains high and is linked to non-AIDS complications. Alongside its other virologic and immunologic benefits, aspirin promisingly appears to lower the residual IA in PLHIV in small studies. Methods: We conducted a double-blind, parallel-group randomised trial involving ART-naïve PLHIV initiating ART at recruitment. Participants were randomly assigned (1:1) to receive 75 mg aspirin or placebo daily for 24 weeks, alongside standard of care. The primary outcome was proportion of participants attaining HIV viral load 0.05. Conclusions: Low-dose aspirin initiated alongside ART through 24 weeks did not impact virologic or immunologic markers among PLHIV. Trial registration: PACTR202003522049711, NCT05525156

Date: 2025
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0331087 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 31087&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0331087

DOI: 10.1371/journal.pone.0331087

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().